JW Pharmaceutical to Present Preclinical Results of Novel Drug Candidate for Rare Pediatric Brain Diseases at World Orphan Drug Congress
JW Pharmaceutical announced on May 14 that it will participate in the '2026 World Orphan Drug Congress USA,' which will be held in Boston, USA, from June 9 to 11, to present the preclinical research results of its novel drug candidate for rare pediatric brain diseases, 'DDC-02 (provisional code name)'.
DDC-02 is a first-in-class oral small-molecule compound being developed as a treatment for rare genetic pediatric brain diseases, including Pitt-Hopkins syndrome.
A view of the JW Pharmaceutical building in Gwacheon, Gyeonggi Province. JW Pharmaceutical
View original imageFocusing on the reduced Wnt signaling observed in these diseases, JW Pharmaceutical has been conducting research on small-molecule new drug substances that can normalize the deficient signaling pathway.
The DDC-02 candidate to be presented this time was derived using JW Pharmaceutical's proprietary AI-based drug development platform, 'JWave.' In particular, genomics analysis through this platform enabled a deeper molecular understanding of the diseases and the mechanism of action, enhancing both research efficiency and precision.
Currently, DDC-02 is undergoing various safety evaluations. JW Pharmaceutical plans to use its presentation at the congress to share research achievements and development potential of this candidate with the global market and to seek diverse opportunities for collaboration.
A JW Pharmaceutical representative stated, "This presentation at the congress is a meaningful opportunity to showcase JW's innovative drug candidate for rare pediatric brain diseases on the global stage. Through in-depth exchanges with experts in the field of rare diseases, we aim to expand opportunities for technological alliances and other collaborations, and to accelerate the development of new drugs that can improve patients' quality of life."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Meanwhile, the World Orphan Drug Congress USA is a global event dedicated to the development of treatments for rare diseases. It brings together major pharmaceutical and biotechnology companies, as well as government and regulatory agencies, patient organizations, and investors—key stakeholders in the rare disease drug development ecosystem—to share the latest trends and innovative case studies.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.